104 related articles for article (PubMed ID: 22388607)
21. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
23. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
[TBL] [Abstract][Full Text] [Related]
24. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
25. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study.
Karie S; Gandjbakhch F; Janus N; Launay-Vacher V; Rozenberg S; Mai Ba CU; Bourgeois P; Deray G
Rheumatology (Oxford); 2008 Mar; 47(3):350-4. PubMed ID: 18238787
[TBL] [Abstract][Full Text] [Related]
26. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs.
de Miguel D; García-Suárez J; Martín Y; Gil-Fernández JJ; Burgaleta C
Nephrol Dial Transplant; 2008 Dec; 23(12):3762-6. PubMed ID: 18779628
[No Abstract] [Full Text] [Related]
27. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study.
Locasciulli A; Mura R; Fraschini D; Gornati G; Scovena E; Gervasoni A; Uderzo C; Masera G
Haematologica; 1992; 77(1):49-53. PubMed ID: 1398282
[TBL] [Abstract][Full Text] [Related]
28. Renal function and methotrexate clearance in children with newly diagnosed leukemia.
Murry DJ; Synold TW; Pui CH; Rodman JH
Pharmacotherapy; 1995; 15(2):144-9. PubMed ID: 7624260
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
31. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
Tatsumoto C; Kawakami K; Nagayama J; Kawano H
Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
[TBL] [Abstract][Full Text] [Related]
32. Advances in individual prediction of methotrexate toxicity: a review.
Schmiegelow K
Br J Haematol; 2009 Sep; 146(5):489-503. PubMed ID: 19538530
[TBL] [Abstract][Full Text] [Related]
33. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.
Razzouk BI; Rose SR; Hongeng S; Wallace D; Smeltzer MP; Zacher M; Pui CH; Hudson MM
J Clin Oncol; 2007 Apr; 25(10):1183-9. PubMed ID: 17401007
[TBL] [Abstract][Full Text] [Related]
34. Polyuria associated with high-dose methotrexate in two patients with acute lymphoblastic leukaemia.
Lau KK; Weiss AR; Jones DP
J Oncol Pharm Pract; 2005 Mar; 11(1):31-3. PubMed ID: 16460601
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study.
Kroft EB; Creemers MC; van den Hoogen FH; Boezeman JB; de Jong EM
Br J Dermatol; 2009 May; 160(5):1075-82. PubMed ID: 19210503
[TBL] [Abstract][Full Text] [Related]
36. High-dose methotrexate in childhood all.
Moe PJ; Holen A
Pediatr Hematol Oncol; 2000 Dec; 17(8):615-22. PubMed ID: 11127393
[TBL] [Abstract][Full Text] [Related]
37. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
Tuffaha HW; Al Omar S
J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686
[TBL] [Abstract][Full Text] [Related]
38. Are glomerular filtration rate estimations necessary before high dose methotrexate?
Rees H; Hann IM; Chessells JM; Webb DK
Arch Dis Child; 1999 Oct; 81(4):339-40. PubMed ID: 10490441
[TBL] [Abstract][Full Text] [Related]
39. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
40. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
